CD28 and acute myeloid leukemia: Ehninger et al. (2022) performed a phase Ia trial in relapsed/refractory (R/R) CD123+ AML patients using next-generation CAR-T cells with CD28 costimulatory domain and a CD123 targeting module (TM).